Case Reports in Oncology (Mar 2023)

Cushing’s Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat

  • Caio Teixeira Heleno,
  • Seung Pyo D. Hong,
  • Hyung-Gyo Cho,
  • Min Jeong Kim,
  • Yeonggyeong Park,
  • Young Kwang Chae

DOI
https://doi.org/10.1159/000527824
Journal volume & issue
Vol. 16, no. 1
pp. 124 – 128

Abstract

Read online

Cushing’s syndrome (CS), secondary to paraneoplastic syndrome, is more commonly seen in small cell lung cancer but never before reported in epidermal growth factor receptor-mutated adenocarcinoma of the lung. Here, we present a case of a patient whose symptoms of hypokalemia, hypertension, and progressive abnormal glucose levels led to further workup that revealed adrenocorticotropic hormone-dependent hypercortisolism. Her cortisol levels dropped after 1 month of osilodrostat treatment, while lung cancer was treated with osimertinib. The use of osilodrostat in paraneoplastic CS has been previously reported in only 3 patients.

Keywords